Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication

22 May 2023

Abstract excerpt

Schlafen 11 (SLFN11) is an increasingly prominent predictive biomarker and a molecular sensor for a wide range of clinical drugs: topoisomerases, PARP and replication inhibitors, and platinum derivatives. To expand the spectrum of drugs and pathways targeting SLFN11, we ran a high-throughput screen with 1,978 mechanistically annotated, oncology-focused compounds in two isogenic pairs of SLFN11-proficient and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to PARP inhibition in cancer therapy
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37216280
DOI: 10.1158/1535-7163.mct-22-0552

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replicationPMID 37216280Read ↗

Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11Semantic proximity Read ↗

The crucial role of single-stranded DNA binding in enhancing sensitivity to DNA-damaging agents for Schlafen 11 and Schlafen 13Semantic proximity Read ↗

SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitorsSemantic proximity Read ↗

SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidanceSemantic proximity Read ↗

SLFN11 is a general target for enhancing the sensitivity of cancer to chemotherapy (DNA-damaging agents)Semantic proximity Read ↗

Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agentsSemantic proximity Read ↗

Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forksSemantic proximity Read ↗

Mechanisms used by cancer cells to tolerate drug-induced replication stressSemantic proximity Read ↗

NEDD8-Targeting Drug MLN4924 Elicits DNA Rereplication by Stabilizing Cdt1 in S Phase, Triggering Checkpoint Activation, Apoptosis, and Senescence in Cancer CellsSemantic proximity Read ↗

High levels of DNA replication initiation factors indicate ATRi sensitivity via excessive origin firingSemantic proximity Read ↗

SLFN11-mediated tRNA regulation induces cell death by disrupting proteostasis in response to DNA-damaging agentsSemantic proximity Read ↗

SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.